





Strategic Directions

Maximising the Value of Partnership
A Brainstorming Discussion



EASL

INTERNATIONAL
LIVER
FOUNDATION

Tbilisi, Georgia, 04.12.2018

Discussion Items

1. Introduction
2. The EASL International Liver Foundation
3. Our Partnership Approach
4. Delivering Value Across Multiple Dimensions
5. Discussions and Next Steps



The EASL International Liver Foundation



EASL

INTERNATIONAL
LIVER
FOUNDATION

Tbilisi, Georgia, 04.12.2018

The EASL International Liver Foundation

MISSION

The EASL International Liver Foundation is a global non-profit organization, established by the European Association for the Study of the Liver (EASL), committed to increasing the quality of life and reducing premature mortality for the greatest number of people by improving liver health. 4 pillars guide our action:

4 PROGRAM PILLARS



THE BOARD OF DIRECTORS



Massimo Colombo
MD, Professor of Medicine, Head of Traslational Liver Research, IRCCS, Humanitas, Milan, Italy, Chairman, EASL International Liver Foundation, Geneva, Switzerland



Christian Bréchet
MD Ph.D, is retired President, Institut Pasteur, Paris, France



Tom H. Karlsen
MD, PhD, Full Professor of Internal Medicine, Oslo University Hospital Rikshospitalet, Norway, Secretary General of EASL, Geneva, Switzerland



Jordi Bruix
is Professor of Medicine at the University of Barcelona and Director of the Barcelona Clinic Liver Cancer (BCLC) Group within the Liver Unit at the Hospital Clinic of Barcelona, Spain



Andrea Sironi
is Professor of Banking and Finance at Bocconi University in Milan. He is Chairman of Borsa Italiana SpA and, member of the Board of Directors of the London Stock Exchange Group.



Benoit Merkt
Dr. iur., Attorney at Law, MJur has been a partner of the Swiss law firm Lenz & Staehelin since 2006. He is co-head of Lenz & Staehelin competition law and non-profit/philanthropy practices.



Mark Thursz
is Professor of Hepatology at Imperial College where he is head of the Digestive Diseases Division and lead clinician for hepatology at St Mary's Hospital, London.



Stefan Wiktor
is Professor of Medicine and Public Health at the University of Washington in Seattle, U.S. He was the Team Lead of the World Health Organization's Global Hepatitis Programme in Geneva, Switzerland.



Philip N. Newsome
Director of the Centre for Liver Research & Professor of Experimental Hepatology, University of Birmingham, and Consultant Hepatologist at the Liver Unit, Queen Elizabeth Hospital, Birmingham, Vice-Secretary General of EASL, Geneva Switzerland



Jeffrey V. Lazarus
associated researcher at the Barcelona Institute of Global Health (ISGlobal), Hospital Clinic, University of Barcelona, Vice Chairman EASL International Liver Foundation, Geneva, Switzerland.



Manal El Sayed
Professor of Paediatrics at Ain Shams University, Cairo, Egypt. Since 2011 Vice Chair of the WHO's Technical Advisory Group for Prevention and Control of Viral Hepatitis in Egypt and supervisor (oversight) of the Egyptian national program for control of viral hepatitis at Ministry of Health.

Striving towards a Bio-engineered Liver



Fostering research in a critical unmet area

In collaboration with Institut Pasteur, Paris, EILF convened a group of world-class experts to provide guidance for turning a vision for the development of a bio-engineered liver into a reality.

The panel concluded with two determinations:

- No single research centre, lab or speciality would be able to solve the many scientific challenges involved in the development of a bio-engineered liver. Thus, **collaboration between centres of excellence** and research teams involving a wide range of specialties (e.g., engineers, bio-engineers, liver stem/progenitor biologists, vascular biologists and hepatologists) would be vital to the success of this initiative.
- Overcoming current funding shortage in the area of regenerative medicine will require the development of an **ambitious fundraising campaign**

Response

- Launch an EASL consortium on regenerative medicine

EASL Consortium for Regenerative Hepatology

The Aim of the Consortium

The EASL Consortium for Regenerative Hepatology is aimed at the delivery of bioengineered tissues and associated biotechnologies for regenerative Hepatology.

Prioritized areas of scientific/technical expertise of consortium

1. Cell sources and cell biology
2. Biomaterials
3. Tissue engineering
4. Safety, ethical and regulatory

Consortium strategy

1. Create a 5% bio-engineered liver mass in order to develop "implantable liver tissue" for the treatment of inherited hepatic metabolic disorders
2. Create bioengineered bile ducts to be used in liver transplant and congenital biliary diseases
3. Create a 30% bio-engineered liver mass for transplantation in patients with acute or acute-on-chronic liver failure

Benefits

The benefits of achieving these outcomes are wide-reaching and will enable

- The direct study of human physiology and pathophysiology, which will have wide-ranging research applications, for example: mechanisms of liver tissue, drug discovery, screening, toxicity testing and bio-marker identification;
- A significant reduction in the need for animal testing;
- Advancement in the development of other bio-engineered organs through the processes, mechanisms, and technologies for tissue engineering identified through this project.

1. University College London, London, United Kingdom

Institute for Liver and Digestive Health: Professor Massimo Pinzani, Dr G. Mazza

Institute for Child Health: Professor Paolo De Coppi

Centre for Cell, Gene and Tissue Therapeutics: Professor Marc Lowdell

2. Centro de Investigacion Biomedica Aragon, Zaragoza, Spain

Professor Pedro Baptista

3. University of Cambridge, Cambridge, United Kingdom

Stem Cell Institute: Professor Ludovic Vallier, Dr Fotis Sampaziotis

4. Universite' Catholique Louvain, Brussels, Belgium

Institute of experimental and Clinical Research: Professor Etienne Sokal

5. University of Basel, Basel, Switzerland

Stem Cell Center of Competence: Dr Andrea Banfi

6. Utrecht University, Utrecht, The Netherlands

Faculty of Veterinary Medicine: Dr Bart Spee, Dr Louis Penning

7. University of Edinburgh, Edinburgh, United Kingdom

MRC Centre for Regenerative Medicine: Professor Stuart Forbes

8. Yale University Medical School, New Haven, CT, USA

Yale Liver Center: Professor Mario Strazzabosco

9. Institut de Duve, Brussels, Belgium

Professor Frederic Le Maigre

10. Medizinische Hochschule Hannover, Hannover, Max Planck Institute Münster and Hannover Germany

CellBiologyCluster-of-Excellence REBIRTH: Professor Tobias Cantz

LIVER TRANSPLANTATION PRECEPTORSHIP

3-Months program available in Geneva, Milan and Barcelona

LIVER CANCER PRECEPTORSHIP

2-weeks program available in Mainz, Paris, Milan, Geneva and Bologna

EILF-GOLD (GUIDANCE ON LIVER DISEASES)

Schools of Excellence and short custom programs (real case studies, public health counselling, guidelines tutoring)

- Jeddah, KSA
- Riyadh, KSA
- Karachi, Pakistan
- Islamabad, Pakistan
- Ulaanbaatar, Mongolia
- Tashkent, Uzbekistan
- Dubai, UAE
- Singapore, Singapore
- Lagos, Nigeria

A network of excellence in HCC management

Europe has been the leader of major advancements in the field of diagnosis and treatment of liver cancer.

Studies conducted in Europe have been instrumental in defining epidemiology, risk factors, diagnostic approach, prognostic evaluation, treatment indication and criteria to select patients for surgical resection, liver transplantation and ablation. Indeed European experts have provided the majority of the data that has resulted in the guidelines that are now followed worldwide.

The Foundation appointed Professor Jordi Bruix to develop and manage the EILF Preceptorship Programme. Based on strict criteria 5 centers of excellence devoted to liver cancer were invited to participate in this programme.

- BCLC. Hospital Clínic. Barcelona.
- University Hospitals Paris-Nord-Val-de-Seine, AP-HP, Beaujon, Paris.
- Istituto Nazionale Tumori, Milan.
- Geneva University Hospitals, Geneva.
- University Medical Center. Johannes Gutenberg University, Mainz.

- The team has to have international standing because of publication track in the field.
- The center has to offer all treatment options: resection, transplant, ablation, TACE and systemic therapy according to current evidence. This secures exposure to all approaches and the involvement of fellows in their application, as well as the feasibility to debate any aspect with the experts in charge.
- Active participation in clinical trials is mandatory. Trials have to be listed in official site such as [trial.gov](https://clinicaltrials.gov).

Viral Hepatitis Elimination



Viral Hepatitis Elimination Consultative Meeting

European Haemophilia Consortium

Vilnius – October 6th, 2017
14.30 – 16.00



ELIMINATING VIRAL HEPATITIS IN THALASSEMIA PATIENTS AN EXPERT CONSULTATIVE MEETING

Thessaloniki 18 November 2017

Where therapy of hepatitis C stands now

Massimo Colombo, MD
Humanitas Hospital/Clinical and Research Center, Rozzano, Italy.
EASL International Liver Foundation, Geneva, Switzerland



Editorial



Micro-elimination – A path to global elimination of hepatitis C

Jeffrey V. Lazarus^{1,2,*}, Stefan Wiktor³, Massimo Colombo⁴, Mark Thursz⁵,
on behalf of the EASL International Liver Foundation

¹Barcelona Institute for Global Health (ISGlobal), Hospital Clinic, University of Barcelona, Barcelona, Spain; ²CHIP, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark; ³Department of Global Health, University of Washington, USA; ⁴Clinical and Research Center Humanitas, Rozzano, Italy; ⁵Division of Digestive Diseases, St Mary's Hospital, Imperial College London, London, UK

VIRAL HEPATITIS ELIMINATION IN AFRICA



AN EXPERT GROUP CONSULTATIVE MEETING

WEDNESDAY, APRIL 11, 2018
08.00AM – 11.00AM

VIRAL HEPATITIS ELIMINATION IN THE MIGRANT POPULATION

A PREVENTION, SCREENING & LINKAGE TO CARE PROJECT
MILAN, ITALY - 2018



PROJECT LEADERS
Dr. Giuseppe Colucci, University of Milan
Prof. Massimo Colombo, EASL International Liver Foundation



An activity funded through an independent grant by Roche Diagnostics International Ltd. in kind support by Dia Pro (Roche Diagnostics International Ltd. is a subsidiary of the Roche Group, a Swiss company).

40 San Patrignano



VIRAL HEPATITIS IN PWID A ROADMAP FOR ELIMINATION IN ITALY

SAN PATRIGNANO COMMUNITY
CORIANO, RIMINI, ITALY
10 OCTOBER 2018



WORKSHOP: TREATING THE INFECTIONS AND PREDISPOSING CAUSES

JUERGEN ROCKSTROH * DAVID LEE THOMAS *
MASSIMO COLOMBO * STEFANO VELLA *
MASSIMO GALLI * ANTONIO BOSCHINI * JORDI
BRUIX * MARIA BUTI * MASSIMO PUOTI *
JEFFREY LAZARUS * ALESSIO AGHEMO * CARLO
FEDERICO PERNO * SALVATORE PETTA

REGISTRATIONS

[HTTP://WWW.WEFREE.IT/EN/WORKSHOP-REGISTRATE](http://www.wefree.it/en/workshop-registrate)

VIRAL HEPATITIS ELIMINATION IN THE MIGRANT POPULATION

A MULTI-STAKEHOLDER
POLICY ROUND TABLE

PALERMO, ITALY
June 25th 2018



SAVE THE DATE

WORKSHOP LEADERS
Prof. Antonio Craxi, University of Palermo
Dr. Tullio Prestileo, Civico e Benfratelli Hospital



UNIVERSITÀ
DEGLI STUDI
DI PALERMO



EASL
INTERNATIONAL
LIVER
FOUNDATION



KIDNEY
MEETS
LIVER

*When the excellence
in renal and liver medicine
come together.*

Awareness

TOGETHER, we will generate a strong call to action to tackle liver diseases, starting from NAFLD.

80% of liver disease is amenable to prevention and cure.

Yet, the world is confronted with a new emerging epidemic, it is called NAFLD and it affects approximately 25% of the world's population.

We are working to place the spotlight on NAFLD and take the first important step needed to generate a call to action by developing an understanding of what governments and key stakeholders such as medical associations and patient groups are currently doing.

These actions will be followed by the development of partnerships promoting public awareness campaigns targeting children and adults.

SHEDDING THE LIGHT ON
AN EMERGING EPIDEMIC

NAFLD Policy Review Briefing

PARIS, FRANCE

12th April 2018

10:00 – 11:30

STUDY LEADERS

Prof. Quentin Anstee

Prof. Helena Cortez Pinto

Prof. Jeffrey V. Lazarus

Our Partnership Approach

1. Impeccable Ethical Standard
2. Regular and Transparent Communication with well-defined Focal Points
3. Lean Project Organizational Process
4. Long-term Partnership Perspective
5. Open to new Solutions



Positioning Georgia as a National HCV Elimination Center of Excellence




EASL

INTERNATIONAL
LIVER
FOUNDATION

Tbilisi, Georgia, 03.12.2018

- Increasing capacity among family physicians & other HCPs in Georgia to support decentralization of HCV Screening, Care and Treatment Service
- Increasing diagnostics capacity
- Providing training for neighbouring countries on all aspects of HCV elimination



- Providing Support for Ongoing and Future Research Needs for the Georgia HCV Elimination Program
 - Care & Treatment
 - Implementation Science
 - Diagnostics & Surveillance

- Dissemination of Best-Practices and Lessons Learned from HCV Elimination through publications & international conferences
- Support in countering mis information attacks (fake news etc...)
- Leveraging Existing Partnerships
- Mapping & Engaging new Partners



Moving Forward



EASL

INTERNATIONAL
LIVER
FOUNDATION

Tbilisi, Georgia, 03.12.2018

Next Steps

1. Agreement on Partnership
 1. Ministry of Internally Displaced Persons from the Occupied Territories, Labour, Health and Social Affairs of Georgia.
 2. National Center for Disease Control and Public Health
 3. Center for Disease Control and Prevention
 4. EASL International Liver Foundation
2. Identify and Prioritize Key Activities for 2019
3. Participation at Decentralization Workshop
4. Participation at EASL 2019 in Vienna